Attovia's $90 Million Series C to Propel Breakthrough Therapies
Deal News | Apr 15, 2025 | venBio Partners LLC
Attovia Therapeutics, a clinical-stage biopharmaceutical company, has secured $90 million in a Series C financing round, spearheaded by Deep Track Capital, to further its research and development programs using proprietary ATTOBODY technology. The funding will enable the advancement of its lead assets, ATTO-1310 and ATTO-3712, aiming to achieve clinical proof of concept, specifically for chronic pruritus and atopic dermatitis treatments. This oversubscribed round attracted new investors such as Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, alongside existing partners including venBio, Goldman Sachs Alternatives, and others. The investment will not only facilitate clinical studies but also foster expansion of its therapeutic pipeline to address additional immune-mediated disorders and pursue potential strategic partnerships.
Sectors
- Biopharmaceuticals
- Venture Capital
Geography
- United States – Attovia Therapeutics is based in San Carlos, California, and the investment round involves prominent U.S. venture capital firms and investors.
Industry
- Biopharmaceuticals – The focus on developing treatments for immune-mediated diseases places Attovia in the biopharmaceutical industry, particularly in early-to-mid-stage clinical research for innovative biologic therapies.
- Venture Capital – The investment in Attovia's Series C round involves several venture capital firms, showcasing venture capital's role in funding and advancing biopharmaceutical innovation.
Financials
- $90 million – The total funding raised in the Series C round led by Deep Track Capital.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Attovia Therapeutics | Target Company | Company | A clinical-stage biopharma company developing treatments for immune-mediated diseases using ATTOBODY technology. |
| Deep Track Capital | Lead Investor | Company | A venture capital firm that spearheaded Attovia's Series C round and will join its Board of Directors. |
| Vida Ventures | Investor | Company | A venture capital firm participating in the Series C round. |
| Sanofi Ventures | Investor | Company | Corporate venture arm of Sanofi that invested in the Series C round. |
| Mirae Asset Capital Life Science | Investor | Company | Investment firm focusing on life sciences, part of the Series C investors. |
| venBio Partners LLC | PE Firm | Company | An existing investor in Attovia, specializing in life science investments. |
| Goldman Sachs Alternatives | Investor | Company | Investment management division of Goldman Sachs, contributing to the Series C round. |
| Rebecca Luse | Board Member | Person | Managing Director at Deep Track Capital joining Attovia's Board of Directors. |